Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
Résultats de la recherche
Tout
-
Dublin, April 17, 2025 (GLOBE NEWSWIRE) -- The "Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic...
-
Dublin, April 10, 2025 (GLOBE NEWSWIRE) -- The "Smart Drug Delivery Systems Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ...
-
Dublin, April 09, 2025 (GLOBE NEWSWIRE) -- The "Nanorobots for Drug Delivery Market by Type (Endogenous Power Driven, Exogenous Power Driven), Procedure Type (Chemotherapy, Radiotherapy),...
-
CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 Billion Anxiety Market...
-
KANSAS CITY, Kan., April 03, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
-
In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025$17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for...
-
Dublin, March 10, 2025 (GLOBE NEWSWIRE) -- The "Connected Drug Delivery Devices Patent Landscape Report" report has been added to ResearchAndMarkets.com's offering.The global connected drug...
-
Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2 CTx-1301 is the First, True, Once-Daily Stimulant Medication to Treat ADHD Over the Entire Active Day KANSAS CITY,...
-
Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "Pharmaceutical Cartridges - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
-
No Serious Adverse Events ReportedSubmission of New Drug Application Targeted for Mid 2025 KANSAS CITY, Kan., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical...